Vision Research, 47, 2923-2933] that contrast sensitivity data provide little evidence for magnocellular deficits in schizophrenia. He also suggests other lines of evidence for such deficits. We respond that these concerns are unfounded, and that these other lines of evidence are weak.
In our recent review (Skottun & Skoyles, 2007a) , we found little evidence for magnocellular deficits in schizophrenia from studies of contrast sensitivity. In response, Keri (2008) states that ''behavioral, electrophysiological and imaging studies" point to magnocellular deficits in schizophrenia, and also raises four specific issues. As delineated below, we find that neither set of concerns requires alteration of our conclusion.
In our view (Skottun & Skoyles, 2007b , 2008 , many of the lines of evidence taken to suggest a magnocellular deficit in schizophrenia are problematic. We mention a few examples. One is backward masking. Rassovsky, Green, Nuechterlein, Breitmeyer, and Mintz (2004) and Green, Nuechterlein, Breitmeyer, Tsuang, and Mintz (2003) found abnormalities under both forward and backward masking and under both Type-A and Type-B masking, even though it is primarily Type-B backward masking which has been postulated to reflect magnocellular activity (Breitmeyer & Ganz, 1976) . Another example is electrophysiological methods which have been reviewed elsewhere (Skottun & Skoyles, 2004 , 2007b , 2007c . Also, anatomical postmortem studies (Selemon & Begovic, 2007) have found no abnormalities in neither the magnocellular nor parvocellular LGN layers. Keri holds up the review of Butler and Javitt (2005) . That paper cited the work of Slaghuis (1998) as evidence for magnocellular deficits. However, Slaghuis (1998) reported uniform reductions in contrast sensitivity. This does not indicate a magnocellular deficit. Also, Butler and Javitt (2005, p.152) stated that the magnocellular system mediates detection of small stimuli. This must be incorrect since the magnocellular system is responsible for the detection of low spatial frequencies, i.e. large stimuli. We now consider the four specific concerns raised by Keri (2008) .
Issue 1. Keri (2008) writes that we ''overemphasize the role of spatial frequency", This seems to disregard our review of temporal contrast sensitivity which is even more negative with regard to providing evidence for magnocellular deficits than the spatial frequency studies, since no temporal studies showed evidence for a magnocellular deficit (see Fig. 3 of Skottun & Skoyles, 2007a) . (In the case of spatial contrast sensitivity, in comparison, there was at least one study consistent with a magnocellular deficit.) Keri (2008) cites evidence that magnocellular neurons can display higher contrast sensitivity than parvocellular neurons at 9 c/deg. We agree that the exact crossover point above which contrast sensitivity is dominated by the parvocellular system can depend on experimental conditions (see Skottun & Skoyles, 2007a, p . 2925 for a discussion). However, irrespective of the exact crossover frequency, a magnocellular deficit will always be most pronounced at low spatial frequencies. Because only one reviewed study reported a low-frequency predominance, we concluded that the spatial tuning of contrast sensitivity loss in schizophrenia is generally not consistent with magnocellular deficits. This conclusion is independent of the exact crossover frequency. Keri (2008) further suggests using chromatic stimulus properties to separate magnocellular and parvocellular visual pathways. Schechter et al. (2005) found statistically significant reductions in N1 amplitude (an electrophysiological measure) to isoluminant chromatic stimulation in schizophrenic subjects. This again seems inconsistent with the existence of a magnocellular deficit. Also, with regard to using isoluminant color to separate parvo-and magnocellular responses, some caution is required since parvocellular neurons respond to both color and luminance. In addition, color and luminance appear to be segregated at the cortical level. It is therefore important to distinguish between responses to color and luminance stimuli on the one hand, and parvo-and magnocellular responses on the other (Skottun & Skoyles, in press-a) . Furthermore, in the case of visual functions which depend on contrast, it is important that the color and luminance stimuli are equated for contrast. This may be problematic since ''color contrast" is not equivalent to ''luminance contrast".
Issue 2. Keri (2008) writes ''[t]o more parsimoniously isolate magnocellular and parvocellular pathways, we used a spatial offset detection (vernier) task . . .". The use of Vernier acuity to assess magnocellular sensitivity is problematic for a variety of reasons. It is our intention to comment on this topic in a separate report. Irrespective, the issue of Vernier acuity does not alter the fact that contrast sensitivity data provide little evidence for magnocellular deficits in schizophrenia.
Issue 3. Keri (2008) writes that we ''. . . did not take into consideration the different characteristics of typical . . . and atypical . . . antipsychotics". Keri cites the work of Chen et al. (2003) which compared temporal contrast sensitivity for patients receiving typical and atypical medication to controls. When we re-plotted their data we found (see Fig. 3g of Skottun & Skoyles, 2007a ) the main difference between the typical and atypical medication was that the group receiving typical medication showed reduced sensitivity near 5 Hz. How to relate this specifically to the magnocellular system is not clear. However, there was, in neither patient group, evidence for suppressed sensitivity at high temporal frequencies as would be predicted from a magnocellular deficit. Also, O'Donnell et al. (2006) studied temporal contrast sensitivity in unmedicated schizophrenic patients. These patients showed generally reduced sensitivity at all temporal frequencies. These results, obviously, cannot be attributed to medication of any kind. (A general reduction in temporal contrast sensitivity is not consistent with a magnocellular deficit.) In our review we did, moreover, discuss the potential effects of medication on the contrast sensitivity data. Our conclusion was that it is difficult to make a link between medication and contrast sensitivity in the studies we discussed. We still think this is the case. Furthermore, the issue of typical versus atypical medication does not alter the fact that the existing contrast sensitivity data offer very little support for the existence of magnocellular deficits in schizophrenia.
Issue 4. Keri (2008) writes: ''. . . when arguing against the overactivity of magnocellular pathways, Skottun and Skoyles did not take into consideration the possibility that magnocellular dysfunctions may change during the course of the illness". First, the main point of our comment about an overactive magnocellular system concerns the finding of reduced sensitivity present in several of the contrast sensitivity studies we reviewed. This appears to conflict with the suggestion, made on the basis of masking studies, that schizophrenic individuals have an overly active magnocellular system. However, as we noted, this apparent conflict vanishes if the notion that the abnormalities reflect magnocellular deficits is relinquished. Second, with regard to the notion that ''magnocellular dysfunction may change during the course of the illness", this, although possible, does not detract from the fact that the published data on contrast sensitivity in schizophrenia provide little evidence for a link between magnocellular deficits and schizophrenia.
In addition to these four points, Keri (2008) writes: ''The severity of visual illusions experienced by the prodromal participants positively correlate with the magnocellular sensitivity values". In support of this Keri references a study (Keri & Benedek, 2007) involving persons who were at high risk for psychosis. This would however imply that magnocellular abnormalities are not specifically linked to the diagnosis of schizophrenia. Also, there is evidence to indicate that the risk for schizophrenia is not related to magnocellular dysfunction (Badcock, 1993) .
The general comment of Keri (2008) was that our focus is too narrow, i.e. that ''it is not sufficient to focus on luminance contrast sensitivity data". It seems, however, that even if substantial evidence existed for magnocellular deficits from tests other than contrast sensitivity, one would still have to account for the fact that tests of contrast sensitivity-which is the most direct psychophysical test of magnocellular sensitivity (Skottun, 2000) -have not provided compelling evidence for magnocellular deficits in connection with schizophrenia.
In conclusion, none of Keri's comments require that we revise or modify our conclusion that the evidence from contrast sensitivity largely fails to offer support for the existence of magnocellular deficits in schizophrenia.
